Immuneering 주식 (NASDAQ: IMRX) 주가, 뉴스, 차트, 주식 조사, 프로필.

Immuneering (NASDAQ:IMRX) 주식 시세 및 뉴스 요약

Immuneering

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Exclusives

Trading Ideas

AAPL

AMZN

APLD

CNEY

GLMD

GOVX

IMRX

INTC

LUMN

LUNR

NDRA

NVDA

PLTR

SMCI

SMMT

TNON

TSLA

WHLR

매일 거래일마다 벤징가 프로(Benzinga Pro)에서 수백 개의 헤드라인과 보도자료가 올라온다. 이는 트레이더들이 전체 시장 및 개별 종목에 대한 최신 뉴스를 확인할 수 있는 소스이다. 2024년 9월에 Benzinga Pro에서 가장 많이 검색된 주식들을 살펴보겠다. 현재 가격과 연초 대비 성과는 9월 30일 기준이며 배당금은 포함되지 않았다.

독점: 9월 벤징가 프로에서 가장 많이 검색된 상위 20개 티커 - 테슬라, 엔비디아, 애플은 어디에?

Immuneering Corporation - Class A Common Stock

Immuneering Corp

Each week,&nbsp;Benzinga&#8217;s Stock Whisper Index&nbsp;uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the&nbsp;<a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Read Also:&nbsp;<a href="https://www.benzinga.com/top-stories/24/11/41718416/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-october-2024-where-do-tesla-nvidia-apple-d" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?</a>
Here's a look at the Benzinga Stock Whisper Index for the week of Nov. 8:
Insmed Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>): The biopharmaceutical company saw increased interest from investors over the week, which comes after the company <a href="https://investor.insmed.com/2024-10-31-Insmed-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Business-Update">reported </a>third-quarter financial results and provided a company update in late October. The company said ARIKAYCE had revenue of $93.4 million in the quarter, up 18% year-over-year. 
Insmed also said its NDA submission for Brensocatib in Bronchiectasis is on track for the fourth quarter and is expected to launch in the U.S. in mid-2025. 
H.C. Wainwright reiterated a Buy rating and $90 price target on the stock <a href="https://www.benzinga.com/quote/INSM/analyst-ratings">after the quarterly results</a>. Truist reiterated a Buy rating and raised the price target from $100 to $105. Investor interest could increase in the coming weeks with the company scheduled to participate in several conferences including ones from Guggenheim (Nov. 11), UBS Global (Nov. 12), Wolfe Research (Nov. 20) and Jefferies (Nov. 21).
Insmed shares were up over 8% in the last five trading days, as seen on the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1">Benzinga Pro chart</a> below, and are up over 140% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="506" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135456/Screenshot-234.png" alt="" class="wp-image-638350" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135456/Screenshot-234.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135456/Screenshot-234-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135456/Screenshot-234-768x389.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Applied Industrial Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIT#NYSE">AIT</a>): The industrial company was one of several in the sector to see strong interest from readers, which could be related to Donald Trump winning<a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election"> the 2024 election.</a> Industrials were a top performing sector under <a href="https://www.benzinga.com/general/politics/24/11/41783357/how-did-s-p-500-sectors-perform-during-trumps-first-term-could-this-time-be-different">Trump&#8217;s previous four years</a> in the White House. 
The company also recently <a href="https://ir.applied.com/news/news-details/2024/Applied-Industrial-Technologies-Reports-Fiscal-2025-First-Quarter-Results/default.aspx">reported </a>first-quarter financial results with earnings per share of $2.36 and revenue of $1.10 billion, beating Street consensus estimates of $2.27 and $1.09 billion respectively. Applied Industrial also increased its fiscal 2025 earnings per share guidance to a range of $9.25 to $10.00, up from prior guidance of $9.20 to $9.95 and ahead of a Street estimate of $9.39. 
Analysts <a href="https://www.benzinga.com/quote/AIT/analyst-ratings">raised their price targets</a> on the stock after the quarterly results. The stock was up over 15% in the last five trading days and is up over 50% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="503" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135510/Screenshot-236.png" alt="" class="wp-image-638351" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135510/Screenshot-236.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135510/Screenshot-236-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135510/Screenshot-236-768x388.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Sprouts Farmers Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>): The specialty grocery retailer saw strong interest from Benzinga readers during the week, which comes after <a href="https://investors.sprouts.com/news/news-details/2024/Sprouts-Farmers-Market-Inc.-Reports-Third-Quarter-2024-Results/default.aspx">recent </a>quarterly results and with shares trading at 52-week highs. The company's third-quarter earnings per share of 91 cents and revenue of $1.90 billion beat Street estimates of 76 cents per share and $1.88 billion respectively.
The company said the third quarter was exceptional and CEO Jack Sinclair highlighted "robust traffic growth." Same store sales were up 8.4% in the third quarter. The company opened nine new stores, ending the quarter with 428 stores in 23 states. 
Goldman Sachs recently <a href="https://www.benzinga.com/quote/SFM/analyst-ratings">maintained a Buy rating </a>on the stock and raised the price target from $127 to $159. Wells Fargo maintained an Equal-Weight rating on the stock and raised the price target from $90 to $130. 
The stock was up over 10% over the last five trading days, and shares are up over 190% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="503" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135528/Screenshot-237.png" alt="" class="wp-image-638353" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135528/Screenshot-237.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135528/Screenshot-237-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135528/Screenshot-237-768x388.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>): The medical devices company saw strong interest from readers over the last week, with shares trading at 52-week highs Friday. 
The company recently reported <a href="https://www.benzinga.com/news/earnings/24/10/41391471/intuitive-surgical-stock-pops-on-q3-earnings-beat-da-vinci-procedures-climb-18-regulatory-clearance">third-quarter financial results </a>with revenue of $2.04 billion beating a Street consensus estimate of $2.0 billion and earnings per share of $1.84 beating a Street consensus estimate of $1.63. Intuitive Surgical reported revenue growth of 17% year-over-year in the quarter, with worldwide da Vinci procedures up 18% year-over-year. 
The company also placed 379 da Vinci systems in the quarter, up from 312 in the prior quarter. There are 9,539 installed da Vinci surgical systems as of the end of the quarter. Intuitive obtained regulatory clearance for the da Vinci 5 surgical system in South Korea in October. 
The earnings report saw several<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41406234/intuitive-surgical-posts-q3-earnings-beat-these-analysts-raise-forecasts-on-dv5-upt"> analysts raise their price targets </a>on the stock. Analysts see the company's updated da Vinci 5 system, which can be used for more types of surgeries as a growth catalyst moving forward. Shares of Intuitive Surgical were up around six percent in the last five days and are up over 60% year-to-date.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="997" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135542/Screenshot-238.png" alt="" class="wp-image-638354" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135542/Screenshot-238.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135542/Screenshot-238-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135542/Screenshot-238-768x387.png 768w" sizes="(max-width: 997px) 100vw, 997px" /></a></figure>
Mueller Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLI#NYSE">MLI</a>): The industrials company was another in the sector that saw increased interest and a soaring stock price, potential from Trump's 2024 election win. The company recently <a href="https://ir.muellerindustries.com/news/press-releases/detail/178/mueller-industries-inc-reports-third-quarter-2024-earnings">reported </a>third-quarter net sales of $997.8 million, beating a Street consensus estimate of $936.0 million and quarterly earnings per share of $1.48, which beat a Street estimate of $1.32. Mueller Industries said the revenue growth came from recently acquired businesses and higher copper prices in the quarter.
"We anticipated that declining interest rates and moderating inflation, combined with the resolution of election related uncertainty, will create a more stable and favorable environment for us," Mueller CEO Greg Christopher said.
The stock was up 13% over the last five days and is up over 100% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="508" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135559/Screenshot-240.png" alt="" class="wp-image-638355" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135559/Screenshot-240.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135559/Screenshot-240-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135559/Screenshot-240-768x392.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Stay tuned for next week&#8217;s report, and follow Benzinga Pro for all the latest headlines and&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<ul>
<li><a href="https://www.benzinga.com/exclusives/24/10/41405659/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">October 18</a></li>
<li><a href="https://www.benzinga.com/real-estate/reit/24/10/41549488/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">October 25</a></li>
<li><a href="https://www.benzinga.com/exclusives/24/11/41693907/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">November 1</a></li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/24/11/41779731/trump-victory-sends-bank-stocks-higher-leading-s-p-500-on-regulatory-hopes">Trump Victory Sends Bank Stocks Higher, Leading S&amp;P 500 On Regulatory Hopes</a></li>
</ul>
Photo: Benzinga

INSM

ISRG

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Financial giants have made a conspicuous bullish move on JPMorgan Chase. Our analysis of options history for JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) revealed 34 unusual trades.
Delving into the details, we found 44% of traders were bullish, while 29% showed bearish tendencies. Out of all the trades we spotted, 9 were puts, with a value of $534,186, and 25 were calls, valued at $1,699,384.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $140.0 to $255.0 for JPMorgan Chase over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for JPMorgan Chase options trades today is 1890.97 with a total volume of 5,138.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for JPMorgan Chase's big money trades within a strike price range of $140.0 to $255.0 over the last 30 days.
<h3>JPMorgan Chase Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731096471_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JPM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$40.85</td>
<td>$40.45</td>
<td>$40.71</td>
<td>$200.00</td>
<td>$407.1K</td>
<td>4.0K</td>
<td align="right">100</td>
</tr>
<tr>
<td>JPM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$8.95</td>
<td>$8.9</td>
<td>$8.95</td>
<td>$240.00</td>
<td>$223.7K</td>
<td>9.3K</td>
<td align="right">358</td>
</tr>
<tr>
<td>JPM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$103.15</td>
<td>$102.0</td>
<td>$102.0</td>
<td>$140.00</td>
<td>$122.3K</td>
<td>199</td>
<td align="right">12</td>
</tr>
<tr>
<td>JPM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$29.05</td>
<td>$26.6</td>
<td>$27.4</td>
<td>$240.00</td>
<td>$109.6K</td>
<td>6</td>
<td align="right">40</td>
</tr>
<tr>
<td>JPM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$1.54</td>
<td>$1.51</td>
<td>$1.53</td>
<td>$235.00</td>
<td>$92.2K</td>
<td>3.4K</td>
<td align="right">843</td>
</tr>
</tbody>
</table>

<h3>About JPMorgan Chase</h3>
JPMorgan Chase is one of the largest and most complex financial institutions in the United States, with nearly $4.1 trillion in assets. It is organized into four major segments--consumer and community banking, corporate and investment banking, commercial banking, and asset and wealth management. JPMorgan operates, and is subject to regulation, in multiple countries.
After a thorough review of the options trading surrounding JPMorgan Chase, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is JPMorgan Chase Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 5,820,469, the JPM's price is up by 0.88%, now at $238.47. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 68 days.</li>
</ul>
<h3>Professional Analyst Ratings for JPMorgan Chase</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $238.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on JPMorgan Chase, which currently sits at a price target of $257. 
&#x2A; Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for JPMorgan Chase, targeting a price of $230. 
&#x2A; Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on JPMorgan Chase with a target price of $241. 
&#x2A; An analyst from Evercore ISI Group persists with their Outperform rating on JPMorgan Chase, maintaining a target price of $230. 
&#x2A; An analyst from Oppenheimer persists with their Outperform rating on JPMorgan Chase, maintaining a target price of $232. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for JPMorgan Chase, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

JPMorgan Chase's Options: A Look at What the Big Money is Thinking

Deep-pocketed investors have adopted a bearish approach towards Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CRM usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 26 extraordinary options activities for Salesforce. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 38% leaning bullish and 42% bearish. Among these notable options, 6 are puts, totaling $342,310, and 20 are calls, amounting to $1,009,133.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $220.0 to $420.0 for Salesforce over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Salesforce's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Salesforce's significant trades, within a strike price range of $220.0 to $420.0, over the past month.
<h3>Salesforce Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731096466_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$5.6</td>
<td>$5.55</td>
<td>$5.55</td>
<td>$260.00</td>
<td>$190.3K</td>
<td>959</td>
<td align="right">355</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$13.1</td>
<td>$11.3</td>
<td>$11.6</td>
<td>$310.00</td>
<td>$111.1K</td>
<td>1.0K</td>
<td align="right">403</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$5.85</td>
<td>$5.7</td>
<td>$5.7</td>
<td>$420.00</td>
<td>$108.8K</td>
<td>490</td>
<td align="right">247</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$84.6</td>
<td>$84.6</td>
<td>$84.6</td>
<td>$230.00</td>
<td>$84.6K</td>
<td>2.0K</td>
<td align="right">10</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$66.4</td>
<td>$65.5</td>
<td>$66.0</td>
<td>$250.00</td>
<td>$66.0K</td>
<td>665</td>
<td align="right">10</td>
</tr>
</tbody>
</table>

<h3>About Salesforce</h3>
Salesforce provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
After a thorough review of the options trading surrounding Salesforce, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Salesforce</h3>
<ul>
<li>With a trading volume of 5,510,389, the price of CRM is up by 3.79%, reaching $322.56.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 19 days from now.</li>
</ul>
<h3>Expert Opinions on Salesforce</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $340.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Oppenheimer downgraded its action to Outperform with a price target of $330. 
&#x2A; Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Salesforce with a target price of $350. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Salesforce with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Salesforce's Options: A Look at What the Big Money is Thinking

Whales with a lot of money to spend have taken a noticeably bearish stance on Energy Transfer.
Looking at options history for Energy Transfer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) we detected 21 trades.
If we consider the specifics of each trade, it is accurate to state that 19% of the investors opened trades with bullish expectations and 42% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $122,400 and 18, calls, for a total amount of $2,008,251.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $1.0 to $17.0 for Energy Transfer over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Energy Transfer's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Energy Transfer's whale activity within a strike price range from $1.0 to $17.0 in the last 30 days. 
<h3>Energy Transfer Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731096461_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ET</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$16.1</td>
<td>$15.95</td>
<td>$16.03</td>
<td>$1.00</td>
<td>$961.8K</td>
<td>0</td>
<td>602</td>
</tr>
<tr>
<td>ET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$0.74</td>
<td>$0.71</td>
<td>$0.74</td>
<td>$17.00</td>
<td>$188.7K</td>
<td>88.8K</td>
<td>11.7K</td>
</tr>
<tr>
<td>ET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$0.72</td>
<td>$0.7</td>
<td>$0.71</td>
<td>$17.00</td>
<td>$88.2K</td>
<td>88.8K</td>
<td>6.6K</td>
</tr>
<tr>
<td>ET</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$12.05</td>
<td>$11.9</td>
<td>$12.05</td>
<td>$5.00</td>
<td>$68.6K</td>
<td>301</td>
<td>57</td>
</tr>
<tr>
<td>ET</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$2.6</td>
<td>$2.56</td>
<td>$2.58</td>
<td>$15.00</td>
<td>$64.5K</td>
<td>51.3K</td>
<td>8.3K</td>
</tr>
</tbody>
</table>

<h3>About Energy Transfer</h3>
Energy Transfer owns one of the largest portfolios of crude oil, natural gas, and natural gas liquid assets in the US, primarily in Texas and the US midcontinent region. Its pipeline network totals 130,000 miles. It also owns gathering and processing facilities, one of the largest fractionation facilities in the US, fuel distribution assets, and the Lake Charles gas liquefaction facility. It combined its publicly traded limited and general partnerships in October 2018.
<h3>Energy Transfer's Current Market Status</h3>
<ul>
<li>Trading volume stands at 18,793,942, with ET's price up by 0.01%, positioned at $17.09.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 96 days.</li>
</ul>
<h3>What The Experts Say On Energy Transfer</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $20.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for Energy Transfer, targeting a price of $20. 
&#x2A; In a cautious move, an analyst from B of A Securities downgraded its rating to Buy, setting a price target of $20. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Energy Transfer options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Behind the Scenes of Energy Transfer's Latest Options Trends

Sony Group Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) has reported that the PlayStation 5 (PS5) has surpassed <a href="https://www.benzinga.com/general/gaming">65 million units sold.</a>
However, the company also revealed that PS5 hardware sales have declined compared to the same period last year. While sales dropped from 8.2 million units to 6.2 million, Sony noted improvements in hardware profitability, Eurogamer <a href="https://www.eurogamer.net/ps5-console-sales-top-65m-as-astro-bot-sells-15m-copies-in-first-month">reported.</a>
<h3 class="wp-block-heading">Software Sales And Network Services</h3>
In contrast to the dip in hardware sales, Sony&#8217;s software sales have remained strong. The company shipped 131.3 million games in the first half of its financial year, with 11.3 million of those being first-party titles. 
See Also: <a href="https://www.benzinga.com/general/gaming/24/11/41720083/unboxing-the-ps5-pro-whats-changed-in-sonys-latest-console-upgrade">Unboxing The PS5 Pro: What&#8217;s Changed In Sony&#8217;s Latest Console Upgrade</a>
Astro Bot, a game released in early September, accounted for 1.5 million of those copies, showing the continued demand for PlayStation's exclusive titles. Ghost of Tsushima also saw continued success, selling 13 million copies across both PS5 and PC.
The report also mentioned that earnings were supported by &#8220;a new sports title&#8221; and &#8220;an action RPG title from China,&#8221; which are believed to be EA Sports FC 25 and Black Myth: Wukong, respectively.
<h3 class="wp-block-heading">PlayStation Plus Subscription Growth Slows</h3>
PlayStation Plus subscriptions, which are a key part of Sony's network services, have shown slower growth. The service now has 116 million subscribers, up from 107 million the previous year. However, there was no additional growth since the previous quarter, indicating a plateau in subscription numbers.
<h3 class="wp-block-heading">Future Strategy: Balancing Single-Player And Live Service Games</h3>
Looking ahead, Sony plans to maintain a balanced portfolio of single-player games, which the company describes as having a higher likelihood of success due to its established intellectual properties. At the same time, Sony is continuing to invest in live service games, which present potential for greater revenue but come with more risk.
"We intend to build on an optimum title portfolio during the current mid-range plan period, that combines single-player games, which are our strength and which have a higher predictability of becoming hits due to our proven IP, with live service games that pursue upside, while taking on a certain amount of risk upon release," Sony stated in its report.
The upcoming PS5 Pro is also part of Sony's future strategy. The new console, which is expected to launch soon, is designed to enhance the PlayStation experience with a selection of games confirmed to be optimized for the upgraded hardware.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/10/41633013/sony-adds-new-death-note-game-to-november-ps-plus">Sony Adds New Death Note Game To November PS Plus</a></li>
</ul>
Image credits: Shutterstock.

Gaming

General

Sony Group Corporation American Depositary Shares

SONY

PS5 Surpasses 65 Million Sales, Hardware Slows

Nature&#8217;s Miracle Holding Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMHI#NASDAQ">NMHI</a>) shares are trading lower by 28.8% to 10 cents Friday afternoon after the company announced a <a href="https://www.benzinga.com/pressreleases/24/11/n41842851/natures-miracle-holding-inc-nmhi-announces-pricing-of-3-million-public-offering">$3 million public offering</a>.
What To Know: The offering includes 24,137,360 units priced at $0.1118 per unit, each comprising one share of common stock, a Series A Warrant for an additional share and a Series B Warrant with shares determined at a later date. 
Additionally, 2,696,271 pre-funded units are being offered at $0.1117 per unit, each containing a pre-funded warrant, a Series A Warrant, and a Series B Warrant. 
The offering is set to close around November 12, pending standard closing conditions.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41849984/powell-brushes-off-trumps-removal-threat-economists-say-2026-could-be-his-last-stand">Powell Brushes Off Trump&#8217;s Removal Threat: Economists Say 2026 Could Be His Last Stand</a>
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, NMHI has a 52-week high of $3.04 and a 52-week low of $0.08.

News

NMHI

Why Nature's Miracle (NMHI) Stock Is Down 28%

Live Nation Entertainment Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) is set to report its third-quarter earnings after trading hours <a href="https://www.benzinga.com/insights/earnings/24/11/41846213/whats-next-live-nation-entertainments-earnings-preview">on Monday, Nov. 11</a>.
Investors anticipate results that could build on the ticket vendor's robust second-quarter performance. 
The parent company of Ticketmaster, Live Nation Concerts and Live Nation Media &amp; Sponsorship, reported mixed results last quarter. Revenue <a href="https://www.benzinga.com/quote/LYV/earnings">reached $6.023 billion</a>, slightly ahead of the $6.018 billion forecast. This marked a 7% year-over-year increase. 
Earnings per share fell short of estimates, reaching $1.03 versus the anticipated $1.06.
Read Also: <a href="https://www.benzinga.com/general/entertainment/24/08/40582093/oasis-fans-rejoice-today-is-gonna-be-the-day-rockers-reunite-after-15-year-family-feud">Oasis Fans Rejoice, &#8216;Today Is Gonna Be The Day&#8217;: Rockers Reunite After 15-Year Family Feud</a>
What To Know: In the second quarter, Live Nation demonstrated strong growth in its core operations, with its concert business continuing to perform well amid high demand for live events. 
The company hosted 39 million fans globally, a 5% increase from the same period last year, and saw its ticketing segment reach 183 million fee-bearing ticket sales year-to-date, up 3%. This steady growth highlights Live Nation's ability to attract large audiences across a diverse array of shows.
Sponsorship revenue remains a key growth driver, rising by 28% year-to-date. CEO Michael Rapino attributed this success to strategic investments in hospitality and infrastructure at Live Nation-operated venues, part of the company&#8217;s broader Venue Nation strategy.
What Else: In terms of financial strength, Live Nation ended the second quarter with $6.4 billion in cash and equivalents, reflecting strong cash generation, including $1.4 billion in cash from operating activities and $635 million in adjusted free cash flow. 
Although operating income faced a minor impact due to one-time accruals, Live Nation expects to achieve double-digit growth in adjusted operating income (AOI) for the year, a positive indicator for the third quarter.
With strong tailwinds in sponsorship and ticket sales, third quarter expectations hinge on continued fan turnout and higher spending at venues. If Live Nation can maintain momentum in these areas, it could offset prior EPS misses and reinforce its dominant position in live entertainment.
Read Also: <a href="https://www.benzinga.com/insights/earnings/24/11/41846213/whats-next-live-nation-entertainments-earnings-preview">What&#8217;s Next: Live Nation Entertainment&#8217;s Earnings Preview</a>
<h3 class="wp-block-heading">How To Buy LYV Stock</h3>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in Live Nation Entertainment&#8217;s case, it is in the Communication Services sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, Live Nation has a 52-week high of $127.64 and a 52-week low of $81.38.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/24/11/41853824/sp-500-breaks-6000-points-dow-soars-above-44000-small-caps-eye-strongest-week-in-4-years-tesla-hits-1-trillion-whats-driving-markets-friday">S&amp;P 500 Breaks 6,000 Points, Dow Soars Above 44,000, Small Caps Eye Strongest Week In 4 Years</a></li>
</ul>
Image: Shutterstock

Entertainment

Live Nation Q3 Earnings Preview: What To Expect After A Strong Q2

During the last three months, 4 analysts shared their evaluations of Artivion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AORT#NYSE">AORT</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $31.25, a high estimate of $33.00, and a low estimate of $30.00. This current average has increased by 6.55% from the previous average price target of $29.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1731096158_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Artivion among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Daniel Stauder</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$33.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Artivion. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Artivion compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Artivion's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Artivion's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AORT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Artivion analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Artivion</h2>
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others.
<h3>Unraveling the Financial Story of Artivion</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Artivion's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 9.82% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Artivion's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -2.16%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -0.72%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Artivion's ROA excels beyond industry benchmarks, reaching -0.27%. This signifies efficient management of assets and strong financial health.
Debt Management: Artivion's debt-to-equity ratio stands notably higher than the industry average, reaching 1.23. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

AORT

Where Artivion Stands With Analysts

Analysts' ratings for Yelp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YELP#NYSE">YELP</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $35.0, a high estimate of $38.00, and a low estimate of $30.00. Highlighting a 14.63% decrease, the current average has fallen from the previous average price target of $41.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1731096150_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Yelp by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colin Sebastian</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Nitin Bansal</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Underperform</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Cory Carpenter</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$35.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Yelp. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Yelp compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Yelp's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Yelp's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/YELP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Yelp analyst ratings.</a>
<h2>All You Need to Know About Yelp</h2>
Yelp Inc operates in the online content market based in the United States. It provides a web-based platform and mobile application to bridge the gap between businesses and consumers. The platform assists consumers through product reviews, tips, photos and videos thereby enabling them in making better buying decisions and posting their feedbacks. Its products and services includes Advertising Products and Business Page Products. In addition, it also lets the buyers directly transact with businesses directly through its platform. Yelp generates revenue mainly from the sale of advertising on its website and mobile app to businesses. The company generates majority of the revenue from United States.
<h3>Yelp: Delving into Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Yelp's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 5.9%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Communication Services sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 10.65%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Yelp's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.22% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.88%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.09.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

YELP

4 Analysts Assess Yelp: What You Need To Know

Throughout the last three months, 6 analysts have evaluated Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Corteva, presenting an average target of $67.17, a high estimate of $71.00, and a low estimate of $62.00. This upward trend is apparent, with the current average reflecting a 5.61% increase from the previous average price target of $63.60.
<img src="https://www.benzinga.com/files/images/story/2024/1731096140_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Corteva. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benjamin Theurer</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$62.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Kristen Owen</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$71.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$68.00</td>
<td>-</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$67.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Corteva. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Corteva compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Corteva's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Corteva's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CTVA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Corteva analyst ratings.</a>
<h2>Get to Know Corteva Better</h2>
Corteva is an agricultural inputs pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop protection products. Seeds generate the majority of profits with the remainder coming from crop protection products. Corteva operates globally, but around half of revenue comes from North America.
<h3>Key Indicators: Corteva's Financial Health</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Corteva's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -61.94%. This indicates a decrease in the company's top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Corteva's net margin excels beyond industry benchmarks, reaching -22.53%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Corteva's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -2.1%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Corteva's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.26% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Corteva's debt-to-equity ratio is below the industry average at 0.23, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTVA

Analyst Ratings For Corteva

Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) has been analyzed by 19 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">8</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $64.79, a high estimate of $82.00, and a low estimate of $47.00. This current average has increased by 16.51% from the previous average price target of $55.61. 
<img src="https://www.benzinga.com/files/images/story/2024/1731096133_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Zillow Gr is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trevor Young</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$50.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Jason Kreyer</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Maria Ripps</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$64.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$82.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$74.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Mike Burton</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$73.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Mark Mahaney</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Chris Kuntarich</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$66.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$62.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$71.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Jay McCanless</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Neutral</td>
<td>$47.00</td>
<td>-</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$66.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$55.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Zillow Gr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Zillow Gr compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Zillow Gr's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Zillow Gr's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ZG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Zillow Gr analyst ratings.</a>
<h2>Unveiling the Story Behind Zillow Gr</h2>
Zillow Group Inc is an Internet-based real estate company that offers its customers an on-demand experience for selling, buying, renting, or financing with transparency and ease The group works with real estate agents, brokers, builders, property managers, and landlords to pair technology with top-notch service. The group has brands such as Zillow, Trulia, StreetEasy, Hotpads, Zillow Rentals, Zillow Home Loans, ShowingTime, Follow Up Boss, Aryeo and others.
<h3>A Deep Dive into Zillow Gr's Financials</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Zillow Gr's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 17.14%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Zillow Gr's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -3.44%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -0.44%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Zillow Gr's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.31%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.25, Zillow Gr adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Zillow Gr

Across the recent three months, 3 analysts have shared their insights on Synaptics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYNA#NASDAQ">SYNA</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Synaptics, presenting an average target of $105.0, a high estimate of $130.00, and a low estimate of $90.00. Highlighting a 5.97% decrease, the current average has fallen from the previous average price target of $111.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1731096125_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Synaptics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$95.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Synaptics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Synaptics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Synaptics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SYNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Synaptics analyst ratings.</a>
<h2>Delving into Synaptics's Background</h2>
Synaptics Inc is a producer of semiconductor solutions for the mobile, PC, and Internet of Things markets. The company develops human interface solutions that enable touch, display, fingerprint, video, audio, voice, AI, and connectivity functions for smartphones, PCs, Internet of Things products, and other electronic devices. Geographically, it derives a majority of revenue from China. The company operates in one segment: the development, marketing, and sale of semiconductor products used in electronic devices and products.
<h3>Synaptics: A Financial Overview</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Synaptics showcased positive performance, achieving a revenue growth rate of 8.84% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Synaptics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 84.2%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Synaptics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 15.42%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Synaptics's ROA stands out, surpassing industry averages. With an impressive ROA of 7.77%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Synaptics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.7.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SYNA

The Analyst Landscape: 3 Takes On Synaptics

Throughout the last three months, 17 analysts have evaluated Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Best Buy Co, presenting an average target of $105.35, a high estimate of $123.00, and a low estimate of $80.00. This upward trend is evident, with the current average reflecting a 11.19% increase from the previous average price target of $94.75.
<img src="https://www.benzinga.com/files/images/story/2024/1731096118_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Best Buy Co. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven Zaccone</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$109.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$117.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Karen Short</td>
<td>Melius Research</td>
<td>Announces</td>
<td>Hold</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$116.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Zachary Fadem</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$95.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Steven Zaccone</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Christopher Horvers</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$111.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Seth Sigman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$95.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$123.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$114.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$107.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$94.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Elizabeth Suzuki</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$80.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$95.00</td>
<td>$95.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Best Buy Co. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Best Buy Co compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Best Buy Co's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Best Buy Co's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BBY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Best Buy Co analyst ratings.</a>
<h2>About Best Buy Co</h2>
With $43.5 billion in consolidated 2023 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8.3% share of the North American market and north of 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid-19 pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
<h3>Best Buy Co: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Best Buy Co's revenue growth over a period of 3 months has faced challenges. As of 31 July, 2024, the company experienced a revenue decline of approximately -3.08%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 3.13%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Best Buy Co's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 9.4%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.92%, the company showcases effective utilization of assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.32, caution is advised due to increased financial risk.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Best Buy Co In The Eyes Of 17 Experts

Shares of metals and materials companies are trading lower. The market may be reacting to China's recent stimulus efforts which have struggled to buoy the economy and business conditions.
&nbsp;
&nbsp;
&nbsp;
&nbsp;
&nbsp;
&nbsp;

WIIM

IGMS

IGM Biosciences shares are trading lower after the company reported worse-than-expected Q3 EPS results.

Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) is reportedly considering the sale of Jeppesen, a navigation unit it acquired in 2000, to reduce its $58 billion debt. <a href="https://www.bloomberg.com/news/articles/2024-11-08/boeing-is-exploring-possible-6-billion-sale-for-jeppesen-unit?srnd=homepage-americas">Bloomberg reported </a>that the company is working with an adviser on a sale that could bring in more than $6 billion. 
The unit, which provides navigation tools to airlines, has already attracted interest from many private equity firms.
The possible divestment follows CEO Kelly Ortberg's review of Boeing's assets to identify units that may no longer align with the company&#8217;s focus on core commercial aircraft production. Ortberg said in an earnings call that he's looking at "whether a business or product fits with the long-term strategy or whether it would be better off someplace else."
Ortberg also confirmed that Boeing will pay employees furloughed during the seven-week strike in Seattle, according to a <a href="https://www.bnnbloomberg.ca/business/company-news/2024/11/08/boeing-ceo-says-furloughed-workers-will-be-paid-for-lost-time/#:~:text=%E2%80%9CAs%20we%20navigated%20through%20the,first%20weeks%20of%20his%20tenure.">BNN Bloomberg report.</a> "We want to acknowledge your support by returning your lost pay," the CEO said in an internal memo. 
However, the company plans more job cuts to reduce costs. Boeing has already been cutting costs with hiring freezes and corporate travel reductions to handle its cash shortage.
BA Price Action: Boeing shares were up 0.67% at $151.99 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="543" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08125901/BA-1-1024x543.png" alt="" class="wp-image-638240" style="width:624px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08125901/BA-1-1024x543.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08125901/BA-1-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08125901/BA-1-768x407.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08125901/BA-1.png 1185w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/legal/24/11/41853052/how-much-is-nintendo-suing-palworld-for-patents-financial-details-unveiled">How Much Is Nintendo Suing Palworld For? Patents, Financial Details Unveiled</a></li>
</ul>
Image Via Shutterstock.

Movers

What's Going On With Boeing Shares Today?

Shares of Expedia Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) are climbing following reports <a href="https://www.benzinga.com/news/24/10/41383838/expedia-shares-rises-by-around-6-whats-going-on">of a potential buyout.</a>
With the stock now overbought, there's a strong chance it could reverse and trend lower. That&#8217;s why our team of trading experts has selected it as our Stock of the Day.
Typically, a stock remains within its usual trading range. However, when investors and traders turn emotional and aggressively buy, they can drive the price above this range. In such cases, the stock is considered &#8220;overbought.&#8221;
Many trading strategies and styles are based on the concept of reversion to the mean. If a stock is overbought, people may start to sell it and this could push the price lower.
There are dozens if not hundreds of ways to measure momentum. They are called indicators. It is important to understand that they are different ways of measuring the same thing. New traders can overcomplicate things by studying too many of them.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41402089/goldman-sachs-highlights-20-top-short-squeeze-opportunities-for-q3-earnings-season">Goldman Sachs Highlights 20 Top Short-Squeeze Opportunities For Q3 Earnings Season</a>
Some traders have had success by using and mastering just a few of these indicators.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="530" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08144115/expe-chart-1024x530.webp" alt="" class="wp-image-638424" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08144115/expe-chart-1024x530.webp 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08144115/expe-chart-300x155.webp 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08144115/expe-chart-768x397.webp 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08144115/expe-chart-1536x795.webp 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08144115/expe-chart.webp 1585w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
The red line on the chart is called a Bollinger Band. It is two standard deviations above the 20-day moving average. This is important because according to statistics and probability theory, 95% of all trading should be within two standard deviations of the mean.
If a stock exceeds this threshold, as Expedia has done, it will draw sellers into the market. They will be expecting a reversion back towards the average and their selling could put pressure on it.
On the bottom part of the chart is the Relative Strength Index (RSI). It is another way to measure momentum. If the blue line exceeds the horizontal red line, it indicates overbought conditions. As you can see, that is the case now. This could also draw sellers into the market.
Other popular momentum indicators include Moving Average Convergence Divergence (MACD), the Commodity Channel Index (CCI), and Stochastics (TAS). These are all available on <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Many rookie traders make things more complicated than they need to be. Part of this is using too many indicators. It may make sense for some traders to only use a few and to become familiar and comfortable with them.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41849984/powell-brushes-off-trumps-removal-threat-economists-say-2026-could-be-his-last-stand">Powell Brushes Off Trump&#8217;s Removal Threat: Economists Say 2026 Could Be His Last Stand</a></li>
</ul>
Photo: II.studio/Shutterstock.com

Technicals

Travel

EXPE

Stock Of The Day: Expedia Appears Overbought And May Reverse

GATO

GOLD

PAAS

SAND

SBSW

Shares of metals and materials companies are trading lower. The sector may be reacting to China's recent stimulus efforts which have struggled to buoy the economy and business conditions.

In the current session, the stock is trading at $116.60, after a 0.46% increase. Over the past month, e.l.f. Beauty Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) stock increased by 8.49%, and in the past year, by 22.36%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1731095785_0.png" alt="Past Year Chart" />

<h3>Comparing e.l.f. Beauty P/E Against Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of 49.61 in the Personal Products industry, e.l.f. Beauty Inc. has a higher P/E ratio of 62.74. Shareholders might be inclined to think that e.l.f. Beauty Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1731095785_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

A Look Into e.l.f. Beauty Inc's Price Over Earnings

Salesforce shares are trading higher after the company announced it will hire 1,000 people for an "AI product sales push" and is also developing artificial intelligence agents.

Merck (NYSE:&nbsp;MRK), known as MSD outside of the United States and Canada, announced that Canada's Drug Agency (CDA) has recommended WINREVAIR&#xAE; (sotatercept) for reimbursement in combination with standard pulmonary arterial hypertension (PAH) therapy, for the treatment of adults with World Health Organization [WHO] Group 1 PAH and Functional Class (FC) II or III.
Sotatercept is the first activin signaling inhibitor therapy for PAH in Canada, a new class of therapy that works by improving the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation in PAH patients.

Global

Merck Announces That Canada's Drug Agency Has Recommended WINREVAIR For Reimbursement In Combination With Standard Pulmonary Arterial Hypertension Therapy, For The Treatment Of Adults With World Health Organization Group 1 PAH And Functional Class II Or III

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Immuneering (IMRX – Research Report), Eli Lilly & Co...

Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), Eli Lilly & Co (LLY) and Teva Pharmaceutical (TEVA)

Immuneering reports Q2 results

Immuneering stock rockets 45% on pancreatic therapy data

In a report released today, Ami Fadia from Needham maintained a Buy rating on Immuneering (IMRX – Research Report), with a price target of $15.00. ...

Positive Phase 2a Trial Data Reinforces Buy Rating for Immuneering's Stock

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Immuneering (IMRX – Research Report), McKesson (MC...

Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), McKesson (MCK) and Neurocrine (NBIX)

Mizuho Securities analyst Graig Suvannavejh has reiterated their bullish stance on IMRX stock, giving a Buy rating on September 12. Graig Suvannave...

Outperform Rating Reaffirmed for Immuneering's Stock Amidst Promising IMM-1-104 Phase 2a Study Results

Smith Micro Software, Datasea, and Immuneering Corp. are the 3 Penny Stocks to watch on September 18, 2024, based on&nbsp;TipRanks' Penny Stock Scr...

3 Penny Stocks to Watch Now, 9/18/24

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immuneering (IMRX – Research Report) and IO Biotech ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Catalyst Watch: Spotlight on Micron, Southwest Airlines, and FOMC speakers

Wall Street Breakfast: The Week Ahead

AERG

ALXO

AZUL

BIRK

BMRN

BRZE

COST

DTSS

ETON

GRDN

HUBS

IART

INTU

IOBT

LGCY

MPAA

NBIX

NXST

PGHL

SFIX

SMSI

TEVA

TURB

VERV

VSTO

ZETA

Health Care

Press Releases

Immuneering Recognizes Melanoma Awareness Month

Earnings

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

Small Cap

Opinion

Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment

Immuneering to Present at the Jefferies Global Healthcare Conference

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Biotech Surges Following Positive Phase 2a Observations

Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer

MGNX

MRUS

ONCY

RHHBY

TSX:ONC

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

Celularity

Clene

Elicio Therapeutics

Gain Therapeutics

Immix Biopharma

Kezar Life Sciences

Monopar Therapeutics

Mural Oncology

OncoCyte

Omega Therapeutics

OS Therapies

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Shattuck Labs

Syros Pharmaceuticals, Inc. - Common Stock

Syros Pharmaceuticals

Needham

Chardan Capital

Mizuho

Jefferies

Oppenheimer

Learn About Cryptocurrency

acf/sidebar-related-posts

Learn about this leading blockchain platform that supports decentralized applications and smart contracts.

What is Ethereum?

Earning interest on your Ethereum is a great way to grow your cryptocurrency holdings. Find out how to earn interest on your Ethereum in 4 easy steps.

How to Earn Interest on Ethereum

Crypto continues to boom in 2024. Explore this list of the best cryptocurrencies to invest in this month. Start building your portfolio now!

10 Best Cryptocurrencies to Invest In for November 2024

10 Best Cryptocurrencies to Invest in for October 2024

Discover the best altcoins to invest in for high potential returns. Our top altcoin picks include Ethereum, Solana, Ripple, Dogecoin, Toncoin.

Top 10 Best Altcoins • Benzinga Crypto

10 Best Altcoins in November 2024

Top Cryptocurrency News

acf/news-feed

Cryptocurrency

Bitcoin, Ethereum Rise, Dogecoin Steady After Fed Cuts Rate: Analyst Predicts Apex Crypto's Next Local Top At $85.4K If This Happens

Cryptocurrency /Money Sidebar

개장가	$1.95
종가	-
거래량 / 평균	196.41K / 5.40M
일 범위	$1.80 - $1.95
52주 범위	1.00 - 8.89
시가 총액	$54.81M
P/E 비율	-
배당 수익률	-
거래소	NASDAQ
RSI	42
매도 수량	6.88%
커버링 기간	1

개장가	$1.95
종가	-
거래량 / 평균	196.41K / 5.40M
일 범위	$1.80 - $1.95
52주 범위	1.00 - 8.89
시가 총액	$54.81M
P/E 비율	-
배당 수익률	-
거래소	NASDAQ
RSI	42
매도 수량	6.88%
커버링 기간	1

Comments

Immuneering

Immuneering 예보

Immuneering (NASDAQ:IMRX) 주식 시세 및 뉴스 요약

최근 뉴스

재무

분석가 추세

분석가 평가

비교

FAQ

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌

종목명

매출 변동
총 변동
EBITDA 변동
EBIT 변동
실적 변동